Feline Vaccines Market Size to Surge USD 3.28 Billion by 2034

Major Key Insights of the Feline Vaccines Market

• By region, North America accounted for the largest market share of 41.8% in 2024.
• By region, Asia Pacific is anticipated to grow at the fastest rate in the market with an 8% CAGR from 2025 to 2034.
• By vaccine type, the inactivated (killed) vaccines segment accounted for the dominating share of 56.4% in 2024.
• By vaccine type, the recombinant vaccines segment is expected to witness a CAGR of 7.4% from 2025 to 2034.
• By disease type, the feline panleukopenia virus (FPV) segment held a dominant presence in the market in 2024, with 40.4% share.
• By disease type, the feline herpesvirus type 1 (FHV-1) segment is set to growing at a solid CAGR of 7.8% from 2025 to 2034.
• By technology, the live attenuated segment registered its dominance with 44.4% over the global feline vaccines market in 2024.
• By technology, the inactivated segment is expected to grow significantly at a CAGR of 7.3% from 2025 to 2034.
• By route of administration, the injectable vaccines segment accounted for the highest market share of 55.5% in 2024.
• By route of administration, the intranasal vaccines segment is expected to witness remarkable growth with a 7.1% CAGR from 2025 to 2034.
• By end-user, the veterinary hospitals segment held the major market share of 52.4% in 2024.
• By end-user, the veterinary clinics segment is projected to grow at a CAGR of 7.6% between 2025 and 2034.

Market Overview

The feline vaccines market encompasses biological preparations designed to enhance immune responses in cats, protecting them from a wide range of infectious diseases such as rabies, feline leukemia, calicivirus, and panleukopenia. These vaccines are broadly categorized into core and non-core types, depending on the disease risk and lifestyle of the animal. Core vaccines are essential for all cats, while non-core vaccines are recommended based on exposure risk. The formulations are available in various delivery forms, including injectable and intranasal routes, ensuring effective immunization and convenience for both veterinarians and pet owners.

The market is witnessing significant growth driven by rapid advancements in vaccine technology, which are improving the safety, efficacy, and longevity of immune protection. Increasing pet adoption rates, rising awareness of feline health, and government initiatives promoting animal welfare are further fueling market demand. Additionally, innovations such as recombinant and DNA-based vaccines are expected to revolutionize disease prevention, enhancing the overall expansion of the feline vaccines market during the forecast period.

AI Shifts in the Feline Vaccines Market

Artificial Intelligence (AI) and Machine Learning (ML) are transforming the feline vaccines market by revolutionizing how vaccines are developed, designed, and distributed. These advanced technologies enable faster and more precise identification of potential antigens the components that trigger immune responses through the analysis of vast biological datasets. By leveraging predictive analytics, researchers can assess the safety, stability, and efficacy of vaccine candidates before clinical trials, significantly reducing development time and costs.

AI-driven generative models and molecular dynamics simulations further enhance vaccine formulation by optimizing components for improved stability, effectiveness, and delivery. This integration of AI into vaccine research and production not only accelerates innovation but also ensures the creation of more targeted and reliable vaccines for feline health. As AI continues to evolve, it is expected to play an increasingly vital role in shaping the next generation of feline vaccine technologies.

Major Trends

• Expansion of Next-Generation Vaccine Platforms: In September 2024, MSD Animal Health, a division of Merck & Co., Inc., expanded its USDA-approved NOBIVAC NXT vaccine platform to include a best-in-class vaccine for protecting cats against feline leukemia virus (FeLV), enhancing disease prevention and vaccine efficacy.
• Community Welfare and Vaccination Initiatives: In May 2025, Alley Cat Allies, in partnership with the Humane Society of Atlantic County (HSAC), achieved a milestone of helping 5,000 cats through its Trap-Neuter-Return (TNR) program. A new grant aims to assist 1,000 additional community cats, focusing on spaying, neutering, and vaccination to promote feline health and population control.
• Mobile Vaccination Clinics for Accessibility: In August 2025, the Monroe County Humane Association (MCHA) launched a walk-in mobile vaccine clinic in Bloomington, Indiana, to make preventive veterinary care more accessible to local pet owners, supported by volunteer veterinarians and staff.
• Innovative Therapeutic Feed Solutions: In September 2025, Virbac, a French veterinary pharmaceutical laboratory, introduced Vikaly, the world’s first medicated feed for cats, representing a groundbreaking therapeutic approach that simplifies administration and improves treatment compliance.

Opportunities

• Rising demand for AI-based vaccine development and predictive modeling to enhance vaccine safety and efficacy.
• Expansion of mobile vaccination clinics and community welfare programs to improve access in developing regions.
• Growing preference for non-invasive vaccine delivery systems such as oral and intranasal vaccines.
• Increasing investments in recombinant and DNA-based vaccine technologies to prevent emerging feline diseases.
• Strategic collaborations between pharmaceutical companies, NGOs, and veterinary organizations to enhance vaccination coverage and awareness.

Regional Insights

The North American market holds a dominant share in the feline vaccines industry, driven by high pet ownership rates, advanced veterinary infrastructure, and strong awareness regarding preventive animal healthcare. The U.S. and Canada are witnessing a steady rise in cat adoption and increasing investments from leading veterinary pharmaceutical companies. Government initiatives promoting animal welfare, coupled with technological advancements such as AI-driven vaccine design, are expected to further boost market growth in this region.

In Europe, the market benefits from strong regulatory frameworks, robust veterinary research, and increasing efforts toward zoonotic disease prevention. Countries such as the U.K., Germany, and France are actively promoting feline vaccination programs and innovative delivery methods like intranasal and oral formulations. The growing focus on sustainable and welfare-centric pet healthcare practices is also expanding market opportunities across the region.

The Asia-Pacific region is emerging as the fastest-growing market, fueled by the expanding pet population, rising disposable income, and growing awareness about pet health in countries such as China, Japan, India, and South Korea. The presence of local vaccine manufacturers and increasing government support for animal health programs are creating a favorable environment for industry expansion.

Recent Developments

• In April 2025, the Texas A&M Gastrointestinal Laboratory (GI Lab) announced a partnership with feline virologist Dr. Julia A. Beatty to study viral causes of liver diseases, including cancer, in cats.
  Beatty, whose team recently discovered the feline “cousin” of the hepatitis B virus, a major cause of liver cancer in humans, is the Chair Professor of Veterinary Medicine and Infectious Diseases at the City University of Hong Kong.
• In July 2025, MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension), a new, once-yearly injectable product to treat and protect dogs from fleas and ticks.

Feline Vaccines Market Key Players

• Zoetis Inc.
• Vetoquinol S.A.
• Indian Immunologicals Ltd.
• HIPRA S.A.
• Dechra Pharmaceuticals PLC
• Bioveta, a.s.
• Bimeda Holdings PLC
• Neogen Corporation
• Bayer Animal Health (now part of Elanco)
• Huvepharma EOOD